Arbutus Biopharma Corp 8-K Filing
Ticker: ABUS · Form: 8-K · Filed: Nov 13, 2025 · CIK: 1447028
| Field | Detail |
|---|---|
| Company | Arbutus Biopharma Corp (ABUS) |
| Form Type | 8-K |
| Filed Date | Nov 13, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Arbutus Biopharma Corp (ticker: ABUS) to the SEC on Nov 13, 2025.
How long is this filing?
Arbutus Biopharma Corp's 8-K filing is 2 pages with approximately 479 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 479 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-11-13 07:31:34
Filing Documents
- f8k_111325.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 88KB
- exh_992.htm (EX-99.2) — 48KB
- exh992_01.jpg (GRAPHIC) — 57KB
- exh992_02.jpg (GRAPHIC) — 185KB
- exh992_03.jpg (GRAPHIC) — 159KB
- exh992_04.jpg (GRAPHIC) — 108KB
- exh992_05.jpg (GRAPHIC) — 169KB
- exh992_06.jpg (GRAPHIC) — 157KB
- exh992_07.jpg (GRAPHIC) — 181KB
- exh992_08.jpg (GRAPHIC) — 43KB
- exh992_09.jpg (GRAPHIC) — 142KB
- exh992_10.jpg (GRAPHIC) — 173KB
- exh992_11.jpg (GRAPHIC) — 149KB
- exh992_12.jpg (GRAPHIC) — 124KB
- exh992_13.jpg (GRAPHIC) — 160KB
- exh992_14.jpg (GRAPHIC) — 152KB
- exh992_15.jpg (GRAPHIC) — 164KB
- exh992_16.jpg (GRAPHIC) — 162KB
- exh992_17.jpg (GRAPHIC) — 162KB
- exh992_18.jpg (GRAPHIC) — 127KB
- exh992_19.jpg (GRAPHIC) — 117KB
- exh992_20.jpg (GRAPHIC) — 145KB
- exh992_21.jpg (GRAPHIC) — 124KB
- exh992_22.jpg (GRAPHIC) — 169KB
- exh992_23.jpg (GRAPHIC) — 142KB
- exh992_24.jpg (GRAPHIC) — 170KB
- exh992_25.jpg (GRAPHIC) — 173KB
- exh992_26.jpg (GRAPHIC) — 44KB
- exh992_27.jpg (GRAPHIC) — 169KB
- exh992_28.jpg (GRAPHIC) — 92KB
- exh992_29.jpg (GRAPHIC) — 112KB
- exh992_30.jpg (GRAPHIC) — 126KB
- exh992_31.jpg (GRAPHIC) — 129KB
- exh992_32.jpg (GRAPHIC) — 69KB
- 0001171843-25-007256.txt ( ) — 6370KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_111325_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 13, 2025, Arbutus Biopharma Corporation (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2025 and certain other information. A copy of the press release is furnished herewith as Exhibit 99.1 hereto and is incorporated by reference herein
01. Other Events
Item 8.01. Other Events. On November 13, 2025, the Company posted an updated corporate presentation on its website at www.arbutusbio.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press release dated November 13, 2025 99.2 Corporate Presentation dated November 13, 2025 104 Cover page interactive data file (formatted as inline XBRL). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Arbutus Biopharma Corporation Date: November 13, 2025 By: /s/ Tuan Nguyen Tuan Nguyen Chief Financial Officer